The first of its kind predictive solution bridges clinical development and commercial strategy to help organizations strengthen commercial positioning

TEL AVIV, Israel: QuantHealth, the category leader in AI-driven clinical trial simulation, today announced the launch of its predictive competitive intelligence solution, an unprecedented capability designed to help life sciences organizations optimize not only for clinical trial success, but for future market leadership.

By integrating clinical and commercial intelligence into R&D, the solution enables pharmaceutical and biotech organizations to make earlier and more informed decisions across portfolio, strategy, trial design, evidence generation, and go-to-market planning - while in early clinical development.

Unlike traditional competitive intelligence approaches that rely on retrospective analysis of media and historical market activity, QuantHealth’s solution predicts both clinical trial-level results and sub-population-level results in order to build the future positioning map. This solution predicts the performance of competitive assets that are still in R&D and in-market, without any sponsor data. It then provides actionable insights for clinical development teams to refine the target patient population and make big-picture decisions related to clinical trial design and capital deployments.

The launch comes when the pharmaceutical industry faces growing pressure to improve development efficiency and commercial execution. Less than 10% of drug candidates ultimately receive regulatory approval, while more than one-third of launched medicines fail to meet commercial expectations, often due to poor market differentiation, inadequate understanding of patient and physician needs, and ineffective launch positioning.

“Clinical development teams have historically separated R&D and commercial decision-making, often addressing go-to-market strategy too late in the process. QuantHealth is bridging the gap between R&D and commercial teams by bringing predictive competitor intelligence directly into clinical development, enabling organizations to evaluate the probability of trial success, but also future market positioning and commercial potential earlier,” said Orr Inbar, CEO and co-founder of QuantHealth.

“Too often, clinical development teams have had to make critical decisions based on historical performance from similar drugs. But in today’s rapidly evolving landscape–with growing complexity and new therapeutic categories emerging–looking in the rearview mirror is no longer enough,” says Inbar.

The solution’s core capabilities are already being used by three of the world’s top 20 pharmaceutical companies across competitive intelligence, clinical development, and commercial strategy teams.

The platform operates as a continuously self-optimizing system that combines purpose-built autonomous AI agents, news and market intelligence, and the industry’s only clinical trial foundation model trained on more than 100 million patient records and validated across more than 600 completed clinical trials.

By enabling organizations to simulate market dynamics while therapies are still in development, QuantHealth aims to help life sciences companies reduce development risk, prioritize high-potential assets, improve launch readiness, and maximize long-term commercial success. To learn more, visit https://quanthealth.ai/.

About QuantHealth

QuantHealth is the global leader for AI clinical trial simulation, bringing together the industry’s most advanced clinical trial simulations portfolio - 600+ trial simulations across 30 diseases with up to 90% prediction accuracy - and the category's largest real-world data set to help life sciences and biotechnology organizations improve the potential of clinical trial successes. QuantHealth solutions use real-world data and predictive modeling to simulate trials at scale, optimize protocols, reduce risk, and accelerate timelines. The company is a trusted partner for twelve of the top 20 global pharmaceutical companies.

Fonte: Business Wire